Merck held talks to buy Swiss biotech MoonLake Immunotherapeutics for more than $3bn

MSD rumoured to be eyeing $3bn+ MoonLake takeover

Faced with the looming loss of patent protection for Keytruda, MSD is reported to be interested in buying Swiss immunology player MoonLake

Biotech Stock Catapults On Rumored Merck Takeover

Biotech stock MoonLake Immunotherapeutics rocketed Tuesday on a report Merck offered to buy it for "more than $3 billion."

Merck's Dealmaking Intensifies With MoonLake Bid As Keytruda Patent Cliff Nears: Report - MoonLake (NASDAQ:MLTX), Merck & Co (NYSE:MRK)

US drug giant Merck & Co Inc (NYSE:MRK) reportedly approached Swiss biotech MoonLake Immunotherapeutics (NASDAQ:MLTX) with a bid exceeding $3 billion. While MoonLake turned down the initial offer, talks may be revived. The potential deal signals renewed dealmaking activity as investor pressure has mounted on Merck to secure new assets, especially as its blockbuster cancer drug Keytruda faces patent expiration as early as 2028. MoonLake Immunothe…

Merck held talks to buy biotech MoonLake for over US$3 billion: FT

MERCK has held talks to buy Swiss biotech MoonLake Immunotherapeutics for more than US$3 billion, the Financial Times reported on Monday, citing three people familiar with the matter.

Merck Held Talks to Buy Biotech MoonLake for Over $3 Billion, FT Reports

Merck & Co., Inc. (MRK) Held Talks Over $3 Billion Acquisition of Swiss ...